Hims & Hers Health, Inc. (HIMS)

NYSE: HIMS · Real-Time Price · USD
57.65
+0.33 (0.58%)
At close: Jul 25, 2025, 4:00 PM
57.69
+0.04 (0.07%)
After-hours: Jul 25, 2025, 7:59 PM EDT
0.58%
Market Cap12.90B
Revenue (ttm)1.78B
Net Income (ttm)164.40M
Shares Out 223.83M
EPS (ttm)0.68
PE Ratio84.56
Forward PE70.13
Dividendn/a
Ex-Dividend Daten/a
Volume46,421,823
Open58.16
Previous Close57.32
Day's Range54.30 - 59.94
52-Week Range13.47 - 72.98
Beta2.02
AnalystsHold
Price Target40.73 (-29.35%)
Earnings DateAug 4, 2025

About HIMS

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]

Founded 2017
Employees 1,637
Stock Exchange NYSE
Ticker Symbol HIMS
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 11 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $40.73, which is a decrease of -29.35% from the latest price.

Price Target
$40.73
(-29.35% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Hims & Hers Stock Could Rocket To Meme Stock Fame — If Short Sellers Feel The Squeeze

Hims & Hers Health, Inc. HIMS has seen a surge in retail investor interest, which positions it as one of the most high-profile candidates for the next “meme stock” rally.

13 hours ago - Benzinga

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options

18 hours ago - GlobeNewsWire

HIMS STOCK NEWS: Hims & Hers Health, Inc. (NYSE:HIMS) is Facing Securities Fraud Allegations – Investors with Losses are Notified to Contact BFA Law by August 25 Deadline

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...

1 day ago - GlobeNewsWire

What's Going On With Hims & Hers Stock Wednesday?

Hims & Hers Health, Inc. HIMS shares are trading 16% higher Wednesday, adding to gains of more than 35% over the past month. Here's a look at what's going on.

2 days ago - Benzinga

Hims stock soars 12% on earning hype but analysts still urge caution: here's why

Hims stock soared 12% today and was trading at $56.00 at press time. Trading volume was way up, and the stock's been on a tear all week.

2 days ago - Invezz

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options If you suffer...

2 days ago - PRNewsWire

HIMS DEADLINE: Lose Money on Hims & Hers Health, Inc. (NYSE:HIMS)? You may have been Affected by Fraud and are Urged to Contact BFA Law by August 25

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...

3 days ago - GlobeNewsWire

How Hims & Hers Health Is Quietly Changing Healthcare

Hims surpassed 2.4 million subscribers with 95% recurring revenue and over 85% retention, driving 111% YoY revenue growth. Average monthly revenue per subscriber rose 50% YoY, showing strong monetizat...

7 days ago - Seeking Alpha

The Big 3: SMR, HIMS, KKR

Nuclear power stocks have surged in recent months, and Kenny Polcari notes NuScale Power (SMR) as no exception. He sees the company's small nuclear reactors playing a key role in powering A.I.

Other symbols: KKRSMR
7 days ago - Schwab Network

Why Hims & Hers Management Might Be Its Most Valuable Asset

Hims & Hers Health is a telehealth leader with strong revenue growth, innovative personalized solutions, and ambitious global expansion plans. Despite traditional valuation metrics suggesting overvalu...

10 days ago - Seeking Alpha

Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - HIMS

LOS ANGELES , July 15, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS)...

10 days ago - PRNewsWire

Hims & Hers to Announce Second Quarter 2025 Financial Results on August 4, 2025

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2025 financial result...

11 days ago - Business Wire

HIMS COURT NOTICE: Hims & Hers Health, Inc. Investors may have been Affected by Fraud – Contact BFA Law by the August 25 Legal Deadline (NYSE:HIMS)

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...

15 days ago - GlobeNewsWire

Novo Nordisk's Canadian drug patent lapses, opening market for Hims & Her Health

Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth company, among others, will now be allowed to make exact copies of Novo's ...

Other symbols: NVO
16 days ago - CNBC Television

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.

Other symbols: NVO
16 days ago - CNBC

Hims & Hers Announces Planned 2026 Expansion to Canada, Following ZAVA Acquisition Completion

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring its affordable, holistic weight loss program ...

16 days ago - Business Wire

Oklo, NuScale, Hims Defy Trump Tariffs - And Power The Russell 2000 Toward New Highs

As tariff fears ripple across markets with President Donald Trump sending tariff letters to 12 countries, small-cap resilience is stealing the spotlight. The Russell 2000 index is soaring toward creat...

Other symbols: OKLOSMR
17 days ago - Benzinga

Hims & Hers Health: Unlocking A $6 Billion Future

Hims & Hers grew Q1 2025 revenue by 111% to $586 million, with adjusted EBITDA nearly tripling to $91 million. Nearly 60% of the 2.4 million subscribers now use personalized treatments, boosting reten...

17 days ago - Seeking Alpha

Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits

Hims & Hers Health, Inc. HIMS is currently experiencing a decline in its stock price, trading lower on Monday. The company's stock has plummeted approximately 18% over the past month, reflecting recen...

18 days ago - Benzinga

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options If you purchased or acquired s...

22 days ago - PRNewsWire

Hims & Hers Can Still Thrive Without GLP-1s

Hims & Hers has achieved explosive revenue and subscriber growth, driven by its direct-to-consumer telehealth model and expanding product lines. The recent termination of the Novo Nordisk partnership ...

24 days ago - Seeking Alpha

Hims & Hers Health: Buy The Novo Nordisk Drama Dip

The Hims & Hers Health investment thesis remains intact, despite the Novo Nordisk partnership ending, due to not being focused on branded GLP-1s. The company has long-term business targets, including ...

25 days ago - Seeking Alpha

Hims & Hers: You Are Missing The Big Picture

Novo Nordisk just killed the deal. But Hims might come out even stronger. Here's why the market got it wrong. GLP-1s are just the tip of the iceberg. Hims is quietly positioning itself as the gateway ...

25 days ago - Seeking Alpha

HIMZ: Buy For Short-Term Gains On Hims & Hers Health, But Be Wary Of The Risks

HIMZ offers 2x leveraged exposure to HIMS, ideal for high-risk, short-term traders seeking amplified volatility, not long-term investors. Recent HIMS volatility, including the Novo Nordisk partnership...

4 weeks ago - Seeking Alpha

Hims & Hers Health, Inc. (NYSE: HIMS) Accused of “Illegal Mass Compounding and Deceptive Marketing” Practices; Investors Urged to Contact Award-Winning Firm, Gibbs Mura

OAKLAND, Calif.--(BUSINESS WIRE)---- $HIMS #ClassAction--Gibbs Mura announces a class action lawsuit has been filed on behalf of Hims & Hers Health, Inc. investors.

4 weeks ago - Business Wire